Strategies for discovering drugs from previously unexplored natural products.

Natural products are the most consistently successful source of drug leads. Despite this, their use in drug discovery has fallen out of favour. Natural products continue to provide greater structural diversity than standard combinatorial chemistry and so they offer major opportunities for finding novel low molecular weight lead structures that are active against a wide range of assay targets. As less than 10% of the world's biodiversity has been tested for biological activity, many more useful natural lead compounds are awaiting discovery. The challenge is how to access this natural chemical diversity.

[1]  R. May.  Marine species richness , 1993, Nature.

[2]  F. WilsonG.D.,et al.  Marine species richness , 1993 .

[3]  D. Clark,et al.  Combinatorial biocatalysis: a natural approach to drug discovery. , 1998, Trends in biotechnology.

[4]  G. Rishton.  Reactive compounds and in vitro false positives in HTS , 1997 .

[5]  M. Hall,et al.  Marine biodiversity as a source of chemical diversity , 1994 .

[6]  E. Sausville,et al.  Natural Product Drug Discovery and Development , 1999 .

[7]  Mahabir P. Gupta,et al.  Natural product drug discovery and development: new perspectives on international collaboration. , 1995, Journal of natural products.

[8]  C P McKay,et al.  Perennial Antarctic lake ice: an oasis for life in a polar desert. , 1998, Science.

[9]  B. Olivera,et al.  The T-superfamily of Conotoxins* , 1999, The Journal of Biological Chemistry.

[10]  H. Reichenbach,et al.  Myxobacteria as Producers of Secondary Metabolites , 2000 .

[11]  L. Katz,et al.  Novel Macrolides Through Genetic Engineering , 2000 .

[12]  Roessner Ca,et al.  GENETICALLY ENGINEERED SYNTHESIS OF NATURAL PRODUCTS: From Alkaloids to Corrins , 1996 .

[13]  C. Roessner,et al.  Genetically engineered synthesis of natural products: from alkaloids to corrins. , 1996, Annual review of microbiology.

[14]  R. Witzig,et al.  The road to indigenous extinction: case study of resource exportation, disease importation, and human rights violations against the Urarina in the Peruvian Amazon. , 1999, Health and human rights.

[15]  Lahana,et al.  How many leads from HTS? , 1999, Drug discovery today.

[16]  P. Landsberg.  Much about time in little space , 1995, Nature.

[17]  M. Suffness,et al.  The National Cooperative Natural Products Drug Discovery Group (NCNPDDG) and International Cooperative Biodiversity Group (ICBG) Programs , 1995 .

[18]  M. Iwu.  Biodiversity prospecting in Nigeria: seeking equity and reciprocity in intellectual property rights through partnership arrangements and capacity building. , 1996, Journal of ethnopharmacology.

[19]  Ralf Thiericke,et al.  Drug Discovery from Nature , 2000 .

[20]  A. Sittenfeld,et al.  Exploring and preserving biodiversity in the tropics: the Costa Rican case , 1993 .

[21]  C. Macilwain.  When rhetoric hits reality in debate on bioprospecting , 1998, Nature.

[22]  Thomas Henkel,et al.  Statistical Investigation into the Structural Complementarity of Natural Products and Synthetic Compounds. , 1999, Angewandte Chemie.

[23]  C. Shih,et al.  In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines , 1999, Cancer Chemotherapy and Pharmacology.

[24]  J. L. Gittleman,et al.  The Future of Biodiversity , 1995, Science.

[25]  R. Verpoorte.  Exploration of nature's chemodiversity: the role of secondary metabolites as leads in drug development , 1998 .

[26]  J Davies,et al.  A study of iterative type II polyketide synthases, using bacterial genes cloned from soil DNA: a means to access and use genes from uncultured microorganisms , 1997, Journal of bacteriology.

[27]  I. Raskin,et al.  Use of plant roots for phytoremediation and molecular farming. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Huber,et al.  The complete genome of the hyperthermophilic bacterium Aquifex aeolicus , 1998, Nature.

[29]  S. Mooberry,et al.  Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent , 1997, International journal of cancer.

[30]  K. Horikoshi,et al.  Biodiversity in deep-sea sites located near the south part of Japan , 1999, Extremophiles.

[31]  D. Cane,et al.  Dissecting and exploiting intermodular communication in polyketide synthases. , 1999, Science.

[32]  R. Thiericke,et al.  The Impact of Natural Products on Drug Discovery , 2000 .

[33]  M. Gollin.  New rules for natural products research , 1999, Nature Biotechnology.

[34]  M. Boyd.  The position of intellectual property rights in drug discovery and development from natural products. , 1996, Journal of ethnopharmacology.

[35]  Strohl,et al.  The role of natural products in a modern drug discovery program. , 2000, Drug discovery today.

[36]  P L Myers,et al.  Will combinatorial chemistry deliver real medicines? , 1997, Current opinion in biotechnology.

[37]  J. T. Staley,et al.  Poles apart: biodiversity and biogeography of sea ice bacteria. , 1999, Annual review of microbiology.

[38]  B. Olivera,et al.  Speciation of Cone Snails and Interspecific Hyperdivergence of Their Venom Peptides: Potential Evolutionary Significance of Introns a , 1999, Annals of the New York Academy of Sciences.

[39]  Philip Hugenholtz,et al.  Impact of Culture-Independent Studies on the Emerging Phylogenetic View of Bacterial Diversity , 1998, Journal of bacteriology.

[40]  D. Karl,et al.  Microorganisms in the accreted ice of Lake Vostok, Antarctica. , 1999, Science.

[41]  C. Khosla,et al.  Cloning and heterologous expression of the epothilone gene cluster. , 2000, Science.

[42]  R. Layer,et al.  Conopeptides: From deadly venoms to novel therapeutics. , 2000, Drug discovery today.

[43]  C. Walsh,et al.  Harnessing the biosynthetic code: combinations, permutations, and mutations. , 1998, Science.

[44]  W. Gerwick,et al.  Curacin D, an antimitotic agent from the marine cyanobacterium Lyngbya majuscula. , 1998, Phytochemistry.

[45]  D. Cowan.  The marine biosphere: a global resource for biotechnology , 1997 .

[46]  R. Dixon.  Plant natural products: the molecular genetic basis of biosynthetic diversity. , 1999, Current opinion in biotechnology.

[47]  H. Pennington,et al.  Millennium bugs , 2000, Nature.

[48]  R. Penn,et al.  Adverse effects associated with the intrathecal administration of ziconotide , 2000, Pain.

[49]  D J Newman,et al.  Natural products in drug discovery and development. , 1997, Journal of natural products.

[50]  D. Hafenbradl,et al.  Pyrolobus fumarii, gen. and sp. nov., represents a novel group of archaea, extending the upper temperature limit for life to 113°C , 1997, Extremophiles.

[51]  T. D. Mays,et al.  Legal issues in sharing the benefits of biodiversity prospecting. , 1996, Journal of ethnopharmacology.

[52]  A. Harvey,et al.  The continuing contribution of biodiversity to drug discovery. , 1998, Current opinion in drug discovery & development.

[53]  C. Pearce,et al.  Biologically active fungal metabolites. , 1997, Advances in applied microbiology.

[54]  Chaitan Khosla,et al.  Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic subunits , 1995, Nature.

[55]  J. Handelsman,et al.  Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. , 1998, Chemistry & biology.

[56]  E. Stackebrandt,et al.  Beutenbergia cavernae gen. nov., sp. nov., an L-lysine-containing actinomycete isolated from a cave. , 1999, International journal of systematic bacteriology.

[57]  R K Julian,et al.  A method for quantitatively differentiating crude natural extracts using high-performance liquid chromatography-electrospray mass spectrometry. , 1998, Analytical chemistry.

[58]  D. Chadwick,et al.  Ethnobotany and the search for new drugs. , 1996 .

[59]  J. Bohlmann,et al.  Plant terpenoid synthases: molecular biology and phylogenetic analysis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  M. Bibb,et al.  Genetic construction and functional analysis of hybrid polyketide synthases containing heterologous acyl carrier proteins , 1993, Journal of bacteriology.

[61]  J. Phillipson,et al.  Plant polyphenols: biologically active compounds or non-selective binders to protein? , 1997, Phytochemistry.

[62]  Axel Zeeck,et al.  The Chemical Screening Approach , 2000 .

[63]  P. Giannakakou,et al.  Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)* , 1997, The Journal of Biological Chemistry.

[64]  B. Olivera,et al.  Post-translationally modified neuropeptides from Conus venoms. , 1999, European journal of biochemistry.